GRI Bio, Inc. (GRI)
| Market Cap | 141.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.79M |
| Shares Out | 2.92M |
| EPS (ttm) | -17.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,703 |
| Open | 48.20 |
| Previous Close | 6.14 |
| Day's Range | 5.80 - 6.31 |
| 52-Week Range | 46.72 - 48.06 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 20, 2023 |
About GRI
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California. [Read more]
Financial Performance
Financial StatementsNews
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
Rapidly advancing c linical pipeline in potential high-value i nflammatory, f ibrotic and a utoimmune d iseases
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
- L ive moderated webcast w i th members of the GRI Bio management team on Wednesday, May 3 rd at 2:00 PM ET
GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell mod...
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
Combined company will operate as GRI Bio , Inc. and advance i nnovative p ipeline of Natural Killer T ( “ NKT ”) modulating therapies for the treatment of i nflammatory, f ibrotic and a utoimmune d i...
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
Vallon's b oard approves 1-for-30 r everse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon...
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
Board of Directors unanimously recommend Vallon stockholders to vote “ FOR ” all proposals outlined in the Company's definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with...
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31...
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17 , 2023 at 1:00 PM ET
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLON
New York, New York--(Newsfile Corp. - December 27, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national s...
SHAREHOLDER ALERT: Weiss Law Investigates Vallon Pharmaceuticals, Inc.
NEW YORK , Dec. 15, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vallon Pharmaceuticals, Inc. ("Vallon" ...
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
Combined company will operate as GRI Bio and advance i nnovative p ipeline of Natural Killer T (NKT) regulating therapies for the treatment of i nflammatory, f ibrotic and a utoimmune d iseases
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develo...
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develop...
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develop...
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develop...
Vallon Pharmaceuticals stock is the biggest gainer and most active after exploring possible sale
Shares of Vallon Pharmaceuticals Inc. VLON, +96.81% skyrocketed 89.0% on massive volume in morning trading Friday after the biopharmaceutical company said it is exploring strategic alternatives, inclu...
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the devel...
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Global b iopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and sma...
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
- Company in ongoing disc ussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with CO...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
- T opline data for p ivotal abuse study of the C ompany's lead investigational program ADAIR expected this quarter
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
– Liv e video webcast presentation on Tuesday, January 25 th at 9:00 AM ET
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
- Survey r esults reinforce existing literature that immediate-release ( IR) amphetamine s, such as Adderall ® , are the most commonly abused preparation of prescription stimulants
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develo...
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
- Topline results f ro m p ivotal SEAL study expected in Q1 2022